Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report)’s share price gapped up prior to trading on Tuesday after HC Wainwright raised their price target on the stock from $61.00 to $63.00. The stock had previously closed at $27.14, but opened at $28.04. HC Wainwright currently has a buy rating on the stock. Mirum Pharmaceuticals shares last traded at $28.20, with a volume of 231,887 shares.
Separately, Raymond James decreased their price target on shares of Mirum Pharmaceuticals from $83.00 to $81.00 and set a “strong-buy” rating on the stock in a research report on Thursday, April 13th.
Insiders Place Their Bets
In other Mirum Pharmaceuticals news, insider Lara Longpre sold 1,004 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $25.65, for a total transaction of $25,752.60. Following the transaction, the insider now directly owns 105,839 shares in the company, valued at approximately $2,714,770.35. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 5,498 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $25.65, for a total transaction of $141,023.70. Following the completion of the sale, the chief executive officer now owns 115,334 shares of the company’s stock, valued at approximately $2,958,317.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Lara Longpre sold 1,004 shares of Mirum Pharmaceuticals stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $25.65, for a total transaction of $25,752.60. Following the sale, the insider now directly owns 105,839 shares of the company’s stock, valued at approximately $2,714,770.35. The disclosure for this sale can be found here. In the last three months, insiders have sold 23,450 shares of company stock worth $635,821. Corporate insiders own 24.06% of the company’s stock.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Mirum Pharmaceuticals Stock Performance
The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -7.45 and a beta of 1.27. The stock’s 50-day simple moving average is $26.84 and its two-hundred day simple moving average is $24.80.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last released its earnings results on Thursday, May 4th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.16. The firm had revenue of $31.60 million during the quarter, compared to analyst estimates of $30.58 million. Mirum Pharmaceuticals had a negative net margin of 134.90% and a negative return on equity of 91.76%. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -2.97 earnings per share for the current year.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.
Featured Articles
- Five stocks we like better than Mirum Pharmaceuticals
- Green Hydrogen Stocks Getting Ready to Deliver Big Gains
- Charles Schwab Gets The Rebound, Time to Buy?
- Is Ebix Inc a Phygital E-Commerce Contender or Pretender?
- 3 Mid-Cap Stocks with Expectations for High-Earnings Growth
- Can Lockheed Martin Fly To A New High In 2023?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
